More Telix Pharmaceuticals Limited news
Telix Pharmaceuticals LimitedASX: TLX

Telix Completes TLX250-CDx (Zircaix) BLA Submission

Jun 2, 2024 at 10:41 PM EDT · Issued by Telix Pharmaceuticals Limited

Filed with ASX · Jun 2, 2024 at 10:41 PM EDT

On 6ix: 6ix.com/news/telix-completes-tlx250-cdx-zircaix-bla-submission

Watch Telix Pharmaceuticals' latest call↗Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call↗

Telix Pharmaceuticals Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Telix Pharmaceuticals Limited on 6ix

Earlier from Telix Pharmaceuticals

  • ProstACT SELECT Study of TLX591 rADC Therapy - Positive rPFSMay 30, 2024
  • Response to ASX QueryMay 28, 2024
  • Telix Submits NDA for New Prostate Cancer Imaging AgentMay 26, 2024
  • Telix Annual General Meeting - PresentationMay 22, 2024
  • Telix Annual General Meeting - Chairman and CEO AddressesMay 22, 2024

Later from Telix Pharmaceuticals

  • Telix Launches Proposed US IPOJun 5, 2024
  • Trading HaltJun 12, 2024
  • Telix Elects to Withdraw from Proposed U.S. ListingJun 13, 2024
  • CMS proposes payment improvement for radiopharma diagnosticsJul 11, 2024
  • Telix Q2 2024 Revenue/Business Highlights, Guidance UpgradeJul 17, 2024
All Telix Pharmaceuticals news releases↗

Follow Telix Pharmaceuticals into a list and get an email when it puts out news.

Follow Telix Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer